You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

Leading medical-scientific event on Hemophilia held in Trieste, Italy

Kedrion-organized congress put replacement therapy, personalization and access to care in the spotlight

read more 

EVENTS

Kedrion scientific symposium at the 2019 PNS Conference in Genoa, Italy

A chance for world Key Opinion Leaders to debate possible new therapies for the treatment of CIPN

read more 

PLASMA & BIOTHERAPIES

First patient enrolled and treated in Kedrion’s CARES10 clinical study

Phase 3 study to assess efficacy, safety and pharmacokinetics of a 10% IVIg in the treatment of adult PID patients

read more 
  1. CORPORATE - 29-06-2015

    Humanitarian programme to reduce the gap in the access to clotting factors

    Kedrion helps the WISH project come true: Italian CNS and the World Federation of Hemophilia sign agreement in London

    read more 
  2. EVENTS - 15-05-2015

    Kedrion Continues Global Expansion with Dedication Ceremony at US Facility

    Biopharma Company Celebrates with Local Guests and Dignitaries in Melville, New York

    read more 
  3. CORPORATE - 30-04-2015

    Kedrion SpA’s Shareholders approve 2014 financial statement

    A 466 million euros’ turnover with a 9,8% rise on 2013

    read more 
  4. EVENTS - 17-04-2015

    Kedrion supported the XI World Hemophilia Day

    An increasingly tailor-made prophylaxis lets sports and hemorrhagic conditions live together

    read more 

Pages

For more information please contact: pressoffice@kedrion.com